[14] El-Shehaby, A.M., El-Khatib, M.M., Marzouk, S., et al. (2013) Relationship of BsmI Polymorphism of Vitamin D Receptor Gene with Left Ventricular Hypertrophy and Atherosclerosis in Hemodialysis Patients. Scandinavian Journal of Clinical and Laboratory Investigation, 73, 75-81.
https://doi.org/10.3109/00365513.2012.743163 [15] Kaufman, B.D., Desai, M., Reddy, S., et al. (2008) Genomic Profiling of Left and Right Ventricular Hypertrophy in Congenital Heart Disease. Journal of Cardiac Failure, 14, 760-767.
https://doi.org/10.1016/j.cardfail.2008.06.002 [16] Blazquez-Medela, A.M., Garcia-Ortiz, L., Gomez-Marcos, M.A., et al. (2012) Osteoprotegerin Is Associated with Cardiovascular Risk in Hypertension and/or Diabetes. European Journal of Clinical Investigation, 42, 548-556.
https://doi.org/10.1111/j.1365-2362.2011.02619.x [17] Noheria, A., Mosley, T.H. and Kullo, I.J. (2010) Association of Serum Osteoprotegerin with Left Ventricular Mass in African American Adults with Hypertension. American Journal of Hypertension, 23, 767-774.
https://doi.org/10.1038/ajh.2010.59 [18] Omland, T., Drazner, M.H., Ueland, T., et al. (2007) Plasma Osteoprotegerin Levels in the General Population: Relation to Indices of Left Ventricular Structure and Function. Hypertension, 49, 1392-1398.
https://doi.org/10.1161/HYPERTENSIONAHA.107.087742 [19] Morinaga, T., Nakagawa, N., Yasuda, H., et al. (1998) Cloning and Characterization of the Gene Encoding Human Osteoprotegerin/Osteoclastogenesis-Inhibitory Factor. European Journal of Biochemistry, 254, 685-691.
https://doi.org/10.1046/j.1432-1327.1998.2540685.x [20] Brandstrom, H., Stiger, F., Kahan, T., et al. (2004) A Single Nucleotide Polymorphism in the Promoter Region of the Osteoprotegerin Gene Is Related to Intima-Media Thickness of the Carotid Artery in Hypertensive Patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA). Blood Press, 13, 152-157.
https://doi.org/10.1080/08037050410035563 [21] Brandstrom, H., Stiger, F., Lind, L., et al. (2002) A Single Nucleotide Polymorphism in the Promoter Region of the Human Gene for Osteoprotegerin Is Related to Vascular Morphology and Function. Biochemical and Biophysical Research Communications, 293, 13-17.
https://doi.org/10.1016/S0006-291X(02)00137-7 [22] Mangena, P., Saban, S., Hlabyago, K., et al. (2016) An Approach to the Young Hypertensive Patient. SAMJ: South African Medical Journal, 106, 36-38.
https://doi.org/10.7196/SAMJ.2016.v106i1.10329 [23] Moreno, M.U., Eiros, R., Gavira, J.J., et al. (2017) The Hypertensive Myocardium: From Microscopic Lesions to Clinical Complications and Outcomes. Medical Clinics, 101, 43-52.
https://doi.org/10.1016/j.mcna.2016.08.002 [24] Bastien, M., Poirier, P., Lemieux, I., et al. (2014) Overview of Epidemiology and Contribution of Obesity to Cardiovascular Disease. Progress in Cardiovascular Diseases, 56, 369-381.
https://doi.org/10.1016/j.pcad.2013.10.016 [25] Arnett, D.K., Li, N., Tang, W., et al. (2009) Genome-Wide Association Study Identifies Single-Nucleotide Polymorphism in KCNB1 Associated with Left Ventricular Mass in Humans: The Hyper GEN Study. BMC Medical Genetics, 10, 43.
https://doi.org/10.1186/1471-2350-10-43 [26] Yoshihara, T., Ishida, M., Kinomura, A., et al. (2004) XRCC3 Deficiency Results in a Defect in Recombination and Increased Endoreduplication in Human Cells. The EMBO Journal, 23, 670-680.
https://doi.org/10.1038/sj.emboj.7600087 [27] Ariyandy, A., Sakai, C., Ishida, M., et al. (2018) XRCC3 Polymorphism Is Associated with Hypertension-Induced Left Ventricular Hypertrophy. Hypertension Research, 41, 426.
https://doi.org/10.1038/s41440-018-0038-0 [28] Shen, A., Hou, X., Yang, D., et al. (2014) Role of Osteoprotegerin and Its Gene Polymorphisms in the Occurrence of Left Ventricular Hypertrophy in Essential Hypertensive Patients. Medicine, 93, e154.
https://doi.org/10.1097/MD.0000000000000154 [29] Bahramali, E., Rajabi, M., Jamshidi, J., et al. (2016) Association of ACE Gene D Polymorphism with Left Ventricular Hypertrophy in Patients with Diastolic Heart Failure: A Case-Control Study. BMJ Open, 6, e010282.
https://doi.org/10.1136/bmjopen-2015-010282 [30] Celczyńska, L., Horst, W., Bychowiec, B., et al. (2011) The Effects of Osteoprotegerin (OPG) Genepolymorphism in Patients with Ischaemic Heart Disease on the Morphology of Coronary Arteries and Bone Mineral Density. Kardiologia Polska (Polish Heart Journal), 69, 573-578. [31] Choe, W.-S., Kim, H.-L., Han, J.-K., et al. (2012) Association between OPG, RANK and RANKL Gene Polymorphisms and Susceptibility to Acute Coronary Syndrome in Korean Population. Journal of Genetics, 91, 87-89.
https://doi.org/10.1007/s12041-012-0131-0 [32] Lavie, C.J., Milani, R.V. and Ventura, H.O. (2009) Obesity and Cardiovascular Disease: Risk Factor, Paradox, and Impact of Weight Loss. Journal of the American College of Cardiology, 53, 1925-1932.
https://doi.org/10.1016/j.jacc.2008.12.068

  
comments powered by Disqus
WJCD Subscription
E-Mail Alert
WJCD Most popular papers
Publication Ethics & OA Statement
WJCD News
Frequently Asked Questions
Recommend to Peers
Recommend to Library
Contact Us

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.